StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

IDEXX Laboratories cash

Cash and short-term investments held at the end of each period.

IDEXX Laboratories's cash was $196.93M at Jun 30, 2026. For fiscal 2025 it was $180.07M, down 37.5% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is $471.93M in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$180.07M-37.5%
FY2024Dec 31, 2024$288.27M-36.5%
FY2023Dec 31, 2023$453.93M+303.3%
FY2022Dec 31, 2022$112.55M-22.1%
FY2021Dec 31, 2021$144.45M-62.4%
FY2020Dec 31, 2020$383.93M+325.0%
FY2019Dec 31, 2019$90.33M-27.0%
FY2018Dec 31, 2018$123.79M-73.8%
FY2017Dec 31, 2017$471.93M+20.4%
FY2016Dec 31, 2016$391.85M+14.4%
FY2015Dec 31, 2015$342.59M+6.2%
FY2014Dec 31, 2014$322.54M+15.6%
FY2013Dec 31, 2013$279.06M+24.6%
FY2012Dec 31, 2012$223.99M+21.8%
FY2011Dec 31, 2011$183.90M+17.2%
FY2010Dec 31, 2010$156.92M+47.0%
FY2009Dec 31, 2009$106.73M+35.3%
FY2008Dec 31, 2008$78.87M+30.7%
FY2007Dec 31, 2007$60.36M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$196.93M+19.6%
Q1 FY2026Mar 31, 2026$200.53M+22.3%
Q4 FY2025Dec 31, 2025$180.07M-37.5%
Q3 FY2025Sep 30, 2025$208.17M-32.6%
Q2 FY2025Jun 30, 2025$164.59M-59.0%
Q1 FY2025Mar 31, 2025$163.97M-58.7%
Q4 FY2024Dec 31, 2024$288.27M-36.5%
Q3 FY2024Sep 30, 2024$308.64M-7.0%
Q2 FY2024Jun 30, 2024$401.59M+202.3%
Q1 FY2024Mar 31, 2024$397.43M+256.9%
Q4 FY2023Dec 31, 2023$453.93M+303.3%
Q3 FY2023Sep 30, 2023$331.70M+234.5%
Q2 FY2023Jun 30, 2023$132.84M+16.2%
Q1 FY2023Mar 31, 2023$111.37M-45.6%
Q4 FY2022Dec 31, 2022$112.55M-22.1%
Q3 FY2022Sep 30, 2022$99.18M-31.7%
Q2 FY2022Jun 30, 2022$114.36M-50.7%
Q1 FY2022Mar 31, 2022$204.62M-41.7%
Q4 FY2021Dec 31, 2021$144.45M-62.4%
Q3 FY2021Sep 30, 2021$145.20M-17.3%
Q2 FY2021Jun 30, 2021$232.13M+120.5%
Q1 FY2021Mar 31, 2021$351.16M+331.4%
Q4 FY2020Dec 31, 2020$383.93M+325.0%
Q3 FY2020Sep 30, 2020$175.59M+68.8%
Q2 FY2020Jun 30, 2020$105.29M-5.0%
Q1 FY2020Mar 31, 2020$81.40M-30.2%
Q4 FY2019Dec 31, 2019$90.33M-27.0%
Q3 FY2019Sep 30, 2019$104.00M-29.2%
Q2 FY2019Jun 30, 2019$110.85M-36.5%
Q1 FY2019Mar 31, 2019$116.62M-26.8%
Q4 FY2018Dec 31, 2018$123.79M-73.8%
Q3 FY2018Sep 30, 2018$146.88M-67.7%
Q2 FY2018Jun 30, 2018$174.56M-58.7%
Q1 FY2018Mar 31, 2018$159.23M-60.2%
Q4 FY2017Dec 31, 2017$471.93M+20.4%
Q3 FY2017Sep 30, 2017$454.10M+16.0%
Q2 FY2017Jun 30, 2017$422.90M–
Q1 FY2017Mar 31, 2017$400.34M–
Q4 FY2016Dec 31, 2016$391.85M–
Q3 FY2016Sep 30, 2016$391.47M–

More IDEXX Laboratories figures

See a number that looks wrong?